Inhibitors of cannabinoid receptors and glucose metabolism

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 4, 2008, Pages 505-511

  Scheen, André J ^a,b   Paquot, Nicolas ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cannabinoid 1 receptor blocker; Endocannabinoid system; Obesity; Rimonabant; Type 2 diabetes

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE 1; ADIPONECTIN; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID SYNTHASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; MESSENGER RNA; METFORMIN; PLACEBO; RIMONABANT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TARANABANT; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CANNABINOID RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ABDOMINAL FAT; ADIPOSE TISSUE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETIC OBESITY; DIET RESTRICTION; DRUG MECHANISM; ENERGY EXPENDITURE; EXERCISE; FATTY ACID OXIDATION; FOOD INTAKE; GENE CLUSTER; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID STORAGE; LIPOGENESIS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW; STEATOSIS; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ANIMAL; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY;

ANIMALIA;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENDOCANNABINOIDS; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID;

EID: 54049129686     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3282fcea11     Document Type: Review

References (59)

1. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141:765-774.
2. Howlett AC, Breivogel CS, Childers SR, et al. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47 (Suppl 1): 345-358.
3. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27:73-100.
4. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3:771-784.
5. Mendizabal VE, Adler-Graschinsky E. Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol 2007; 151:427-440.
6. Xie S, Furjanic MA, Ferrara JJ, et al. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use. J Clin Pharm Ther 2007; 32:209-231.
7. Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 2006; 114:974-984.
8. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8:585-589.
9. Carai MA, Colombo G, Maccioni P, Gessa GL Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 2006; 1 2:91-99.
10. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370:1706-1713.
11. Van Gaal LF, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the RIO program. Diabetes Care 2008; 31 (Suppl 2):S229-S240.
12. Scheen AJ. Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007; 21:535-553.
13. Scheen AJ. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol 2008; 20 (Suppl 1):S139-S146.
14. Scheen AJ.The endocannabinoid system, a promising target for the manage-ment of type 2 diabetes. Curr Protein Pept Sci (in press).
15. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18:27-37.
16. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54:2838-2843.
17. Gonthier MP, Hoareau L, Festy F, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity 2007; 15:837-845.
18. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregula-tion of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91:3171-3180.
19. Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55:3053-3060.
20. Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obesity 2007; 31:692-699.
21. Kempf K, Hector J, Strate T, et al. Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity. Horm Metabol Res 2007; 39:596-600.
22. Murdolo G, Kempf K, Hammarstedt A, et al. Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest 2007; 30:RC17-RC21.
23. Lofgren P, Sjolin E, Wahlen K, Hoffstedt J. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 2007; 92:1555-1559.
24. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 2005; 83:944-954.
25. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115:1298-1305.
26. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR14171 6 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord 2005; 29:183-187.
27. 2+ signals and insulin secretion in pancreatic beta-cells. Cell Calcium 2006; 39:155-162.
28. Lafontan M, Piazza PV, Girard J. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab 2007; 33:85-95.
29. Pacher P, Batkai S, Kunos G. The endocannabioid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58:389-462.
30. Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs 2006; 15:307-315.
31. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006; 4:4.
32. Henness S, Robinson DM, Lyseng-Williamson KA. Rimonabant. Drugs 2006; 66:2109-2119.
33. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005; 76:1307-1324.
34. Muccioli GG. Blocking the cannabinoid receptors: drug candidates and therapeutic promises. Chem Biodivers 2007; 4:1805-1827.
35. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28:640-648.
36. Ravinet Trillou C, Arnone M, Delgorge C, et al. Antiobesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284:R345-R353.
37. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112:423-431.
38. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19:1567-1569.
39. Pagano C, Pilon C, Calcagno A, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007; 92:4810-4819.
40. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005; 6:13-21.
41. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63:908-914.
42. Zheng D, CatalanoKJ,Chiu JD, et al. Rimonabant, a selective CB1 antagonist, increases plasma adiponectin independent of omental fat [Abstract].Diabetes 2007; 56 (Suppl 1):A358.
43. Gary-Bobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46:122-129.
44. Banasch M, Goetze O, Schmidt WE, Meier JJ. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis. Liver Int 2007; 27: 1152-1155.
45. Luyckx FH, Scheen AJ, Lefebvre PJ. Nonalcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000; 26:98-106.
46. Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med 2005; 37:347-356.
47. Cavuoto P, McAinch AJ, Hatzinikolas G, et al. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 2007; 267: 63-69.
48. Bermudez-Silva FJ, Suarez J, Baixeras E, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008; 51:476-487.
49. 2+ oscillation in islet β-cells via CB1 receptors. Regul Pept 2008; 145:49-53.
50. Bermudez-Silva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006; 531:282-284.
51. Bermudez-Silva FJ, Suarez J, Sanchez Vera I, et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007; 565:207-211.
52. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389-1397.
53. Van Gaal LF, Scheen AJ, Rissanen AM, et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: 2-year results from the RIO-Europe Study. Eur Heart J 2008. [Epub ahead of print].
54. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA 2006; 295:761-775.
55. Després JP, Golay A, Sjöström L,Rimonabant in Obesity-Lipids Study Group. Effects on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121-2134.
56. Després JP, Van Gaal L, Golay A, Rissanen A. Rimonabant improves oral glucose tolerance in nondiabetic overweight/obese patients with/without comorbidities [Abstract]. Diabetes 2006; 55 (Suppl 1):A80-A81.
57. Scheen AJ, Finer N, Hollander P, et al., for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368:1660-1672.
58. Rosenstock J, Iranmanesh A, Hollander PA. Improved glycemic control with weight loss plus beneficial effects on atherogenic dyslipidemia with rimonabant in drug-näive type 2 diabetes: the SERENADE trial [Abstract]. Diabetes 2007; 56 (Suppl 1):A49-A50.
59. Addy C, Wright H, Van Laere K, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008; 7:68-78.